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Abstract
Objective To determine whether a history of cerebrovascular disease (CVD) increases risk of severe coronavirus disease 
2019 (COVID-19).
Methods In a retrospective multicenter study, we retrieved individual data from in-patients treated March 1 to April 15, 
2020 from COVID-19 registries of three hospitals in Saxony, Germany. We also performed a systematic review and meta-
analysis following PRISMA recommendations using PubMed, EMBASE, Cochrane Library databases and bibliographies 
of identified papers (last search on April 11, 2020) and pooled data with those deriving from our multicenter study. Of 3762 
records identified, 11 eligible observational studies of laboratory-confirmed COVID-19 patients were included in quantita-
tive data synthesis.
Risk ratios (RR) of severe COVID-19 according to history of CVD were pooled using DerSimonian and Laird random effects 
model. Between-study heterogeneity was assessed using Cochran’s Q and I2-statistics. Severity of COVID-19 according to 
definitions applied in included studies was the main outcome. Sensitivity analyses were conducted for clusters of studies 
with equal definitions of severity.
Results Pooled analysis included data from 1906 laboratory-confirmed COVID-19 patients (43.9% females, median age 
ranging from 39 to 76 years). Patients with previous CVD had higher risk of severe COVID-19 than those without [RR 2.07, 
95% confidence interval (CI) 1.52–2.81; p < 0.0001]. This association was also observed in clusters of studies that defined 
severe manifestation of the disease by clinical parameters (RR 1.44, 95% CI 1.22–1.71; p < 0.0001), necessity of intensive 
care (RR 2.79, 95% CI 1.83–4.24; p < 0.0001) and in-hospital death (RR 2.18, 95% CI 1.75–2.7; p < 0.0001).
Conclusion A history of CVD might constitute an important risk factor of unfavorable clinical course of COVID-19  sug-
gesting a need of tailored infection prevention and clinical management strategies for this population at risk.
Keywords Cerebrovascular disease · Stroke · Prognosis · Critical care · COVID-19
Introduction
Rapid transmission of the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) and a case fatality rate that is 
up to 40 times higher than mortality of seasonal influenza 
make coronavirus disease 2019 a global threat [1, 2]. The 
latter is largely explained by high risk of acute respiratory 
distress syndrome as well as sepsis, multi-organ failure and 
disseminated intravascular coagulopathy, which is most 
pronounced in the elderly and in premorbid patients with a 
cardiovascular risk profile [3, 4]. In fact, patients with severe 
course of COVID-19 have up to threefold higher rates of pre-
existing cardiovascular morbidity than patients with mild or 
moderate clinical manifestations [5].
Investigation of early cohorts of COVID-19 patients in 
China focused on the effects of classic cardiovascular risk 
factors such as arterial hypertension and coronary heart 
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disease or comorbidity in general [6, 7]. By contrast, the 
importance of cerebrovascular disease (CVD) in the clinical 
course of COVID-19 is poorly understood. This is a relevant 
research gap as patients with CVD are particularly vulner-
able toward pulmonary and inflammatory complications 
due to their frequent disability [8, 9]. At this stage of the 
pandemic, where overall comorbidity has been established 
as substantial risk factor, in-depth characterization of par-
ticularly endangered individuals might help design tailored 
infection prevention plans. Therefore, we aimed to assess 
whether history of CVD is associated with severe COVID-
19. To approach this question, we assessed individual multi-
center data from three cohorts of COVID-19 patients treated 
during the first months of the pandemic in Germany. In order 
to assess consistency among regions and increase general-
izability of our findings, we then went on to pool our data 
with published data of COVID-19 patients who were being 




In a retrospective multicenter study, consecutive patients 
≥ 18 years with laboratory-confirmed diagnosis of COVID-
19 who have been admitted to the three participating hos-
pitals (University Hospital Carl Gustav Carus Dresden, 
Klinikum Chemnitz gGmbH, Elblandklinikum Meißen) 
in Saxony, Germany between March 1 and April 15, 2020 
were selected from the ongoing COVID-19 registries. 
Locations of participating hospitals are illustrated in Fig. 1. 
Laboratory tests for detection of SARS-CoV-2 included 
real-time reverse transcription polymerase chain reaction 
(RT-PCR) assays (RealStar® SARS-CoV-2 RT-PCR Kit 
RUO, Altona Diagnostics, Hamburg, Germany; Allplex™ 
2019-nCoV Assay, Seegene Inc., Seoul, Republic of Korea; 
GeneFinderTM COVID-19 Plus RealAmp, Osang Health-
care Co., Gyeonggi-do, Republic of Korea) on respiratory 
specimen from nasal or oropharyngeal swab. We obtained 
data on age, sex and vascular comorbidities including arte-
rial hypertension, hyperlipidemia, diabetes mellitus, atrial 
Fig. 1  Map of study sites in Germany where individual data on 
patients with COVID-19 were retrieved. Location of participating 
sites in Saxony, Germany, with rates of confirmed infections with 
SARS CoV-2 based on epidemiological data provided by Robert 
Koch Institute as of April 15, 2020 (www.rki.de/EN/Home/homep 
age_node.html). Numbers in brackets refer to absolute numbers of 
patients included in the multicenter cohort
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fibrillation, coronary heart disease, tobacco use and past 
history of CVD. Cerebrovascular disease was subdivided 
into ischemic stroke, transient ischemic attack and intrac-
erebral hemorrhage. We also reviewed medical records and 
neuroimaging reports from cranial computed tomography or 
magnetic resonance imaging studies for evidence of previous 
clinically apparent or silent CVD. We detected one patient 
with evidence of previous lacunar stroke on cranial magnetic 
resonance imaging that was not diagnosed history of CVD 
and decided to include this patient in our analysis.
Severity outcomes
In order to assess the association of past history of CVD and 
risk of severe clinical course of COVID-19, we aimed to 
classify all patients in our multicenter cohort into “severe” 
and “non-severe” COVID-19. However, previously pub-
lished approaches to categorize severity of COVID-19 were 
found to be inconsistent and all together three different most 
frequently reported approaches could be identified. In order 
to achieve comparability of outcome data with previously 
published cohorts, we separately applied these methods to 
dichotomize our patients into severe and non-severe clinical 
course of the disease. First, we classified severity of COVID-
19 in the patients of our multicenter cohort based on clinical 
parameters according to the classification by the National 
Health Commission guidelines on the Diagnosis and Treat-
ment of COVID-19 [10]. In this classification, “mild” was 
defined as mild clinical symptoms with no signs of pneumo-
nia on chest imaging; “moderate” as fever, respiratory symp-
toms with radiologic signs of pneumonia; “severe” as res-
piratory distress with respiratory rate ≥ 30 per minute and/
or oxygen saturation at rest ≤ 93% and/or oxygenation index 
≤ 300 mmHg and/or progression of pulmonary lesion size 
> 50% within 48 h, “critical” as respiratory failure requiring 
mechanical ventilation, hemodynamic shock, or any other 
organ failure with necessity of intensive care.
We also categorized stages of disease by using the Lean 
European Open Survey on SARS-CoV-2 Infected Patients 
(LEOSS) definition, comprising the following disease 
stages: “uncomplicated”, asymptomatic or symptoms of 
upper respiratory tract infection, nausea, emesis, diarrhea, 
fever; “complicated”, need for oxygen supplementation, 
partial arterial oxygen pressure at room air < 70 mmHg, 
oxygen saturation at room air < 90%, aspartate aminotrans-
ferase or alanine aminotransferase > 5-fold upper limit 
normal, new cardiac arrhythmias, new pericardial effusion 
> 1 cm, new heart failure with pulmonary edema, conges-
tive hepatopathy or peripheral edema; “critical”, need for 
catecholamines, life-threatening cardiac arrhythmia, invasive 
or non-invasive mechanical ventilation, liver failure with 
< 50% Quick value (equaling approximately > 1.55 interna-
tional normalized ratio), quick Sequential [Sepsis-Related] 
Organ Failure-Assessment score ≥ 2, renal failure in need 
of dialysis; “recovery”, improvement by one phase and 
defervescence [11]. Second, severity of COVID-19 was 
also dichotomized for in-hospital death versus survival with 
death equaling severe and survival indicating non-severe 
course. Third, patients were classified into severe or non-
severe clinical course of COVID-19 based on whether they 
required intensive care unit (ICU) treatment or underwent 
regular in-patient care until discharge.
Literature search and study eligibility
This systematic review and meta-analysis complied with the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) recommendations [12]. We systemati-
cally searched electronic databases including MEDLINE 
(accessed by PubMed), EMBASE and Cochrane Library 
for identification of all available observational studies that 
reported on laboratory-confirmed COVID-19 patients aged 
≥18 years with information given on disease severity and 
past history of CVD. In addition, bibliographies of identified 
full-text articles and those of relevant review articles were 
searched manually. In order to be exhaustive, we limited 
our search on electronic databases to search term “COVID-
19” with combinations of associated medical subject head-
ings (MeSH) “COVID-2019”, “severe acute respiratory 
syndrome coronavirus 2”, “2019-nCoV”, “SARS-CoV-2”, 
“2019nCoV”, “Wuhan”, “coronavirus”, “2019/12”. The 
complete search algorithm is provided in Online Resource 1.
Our systematic search covered publications from the ear-
liest date available until our last search date April 11, 2020. 
No language or other restrictions were imposed. All identi-
fied articles were screened using the following eligibility 
criteria: (1) observational cohorts consisting of a minimum 
of five patients ≥ 18 years who have been hospitalized for 
COVID-19 laboratory-confirmed by nasal or oropharyngeal 
swab RT-PCR; (2) data available on past history of CVD; 
(3) categorization of COVID-19 severity according to study-
specific outcome definitions.
Assessment of identified articles involved three steps: 
screening of titles, abstracts and full texts by two independ-
ent reviewers (T.S. and K.B.). Any disagreements were 
resolved by consensus. Abstracts that did not provide suf-
ficient information for analysis of methodology were subject 
to full-text evaluation. In case of missing information or any 
obscurities, the corresponding authors of the identified arti-
cles were contacted for clarification.
Two reviewers (T.S. and K.B.) independently extracted 
data on included studies from the full-text articles with 
insertion into a standardized data extraction form (Excel, 
Microsoft, Redmond, WA, USA). Extracted variables were 
first author, publication year, study design, sample size, 
demographic values, vascular comorbidities including 
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history of CVD as well as definition of severity outcomes 
of COVID-19 and respective absolute numbers of outcome 
events.
Rating of the quality of evidence
We used the Oxford Centre for Evidence-based Medicine 
Rating Scale to assess the quality of evidence in the included 
individual studies [13]. Quality assessment was indepen-
dently performed by two investigators (T.S. and K.B.) and 
disagreements were resolved by consensus.
Statistical analysis
Multicenter study
In the multicenter study, continuous and non-continuous 
variables are presented as median with interquartile range 
(IQR) for skewed data and percentages for proportional 
data. Between-group comparisons were performed using 
Chi-square test, Fisher’s exact test and Mann–Whitney U 
test, where applicable. Multivariable logistic regression was 
performed to explore the predictive value of history of CVD 
for severity outcomes of COVID-19 including clinical sever-
ity according to the classification by the National Health 
Commission guidelines on the Diagnosis and Treatment of 
COVID-19, in-hospital death and necessity of intensive care 
[10]. Candidate variables were identified from the between-
group comparisons, whereas a p value of ≤ 0.25 was used 
for covariate inclusion in the multivariable model. The final 
model was conducted using a backward selection procedure, 
whereas covariates with a p value <0.1 were removed from 
the model.
Pooled analysis
In the quantitative data synthesis, risk ratios (RR) and their 
corresponding 95% confidence intervals (95% CI) for his-
tory of CVD were calculated from the absolute numbers of 
patients with severe and non-severe COVID-19 outcomes 
as provided by each study. In our main analysis, we used a 
composite dichotomized outcome of severity subsuming all 
severity outcomes that were reported by each of the included 
studies comprising severity based on clinical parameters, 
in-hospital death versus survival and necessity of intensive 
care versus regular in-patient care. If included studies classi-
fied severity outcome based on clinical parameters into more 
than two categories (e.g., mild, moderate, severe, critical), 
those were subsumed under severe (i.e., severe and critical) 
and non-severe (i.e., mild and moderate) categories. Thus, 
in our main analysis, all patients reported in studies identi-
fied from literature search cohort were classified into severe 
or non-severe COVID-19 based on the classification used 
by each study. With respect to our multicenter study, we 
chose to apply the approach of defining severity by clini-
cal parameters as recommended by the National Health 
Commission guidelines on the Diagnosis and Treatment of 
COVID-19 since this tended to be the most widely acknowl-
edged method in the literature [10]. Continuity correction 
of 0.5 was used for studies with a zero cell [14]. If a study 
reported two or more zero-cell events, it was excluded from 
respective analysis. DerSimonian and Laird random effects 
model was used to compute the pooled RR for included stud-
ies. [15]
In order to allow separate assessment of clusters of stud-
ies with equal definitions of COVID-19 in conjunction with 
our multicenter data, sensitivity analyses were conducted for 
severity outcomes. We clustered studies that used the same 
approach to define severity and pooled these data with our 
multicenter data by applying the same severity definition 
to our local cohorts. Analyses were carried out for three 
clusters of studies: first, studies defining severity based on 
clinical parameters; second, studies defining severity based 
on necessity of intensive care; third, those defining severity 
by in-hospital death.
Assuming that only available cases with complete data on 
disease severity outcomes were reported in included stud-
ies, pairwise deletion method was used to handle missing 
outcome data. Between-study heterogeneity was assessed 
using Cochran’s Q test and I2 statistics, where I2 values of 
0–40% indicated absent or low, 30–60% moderate, 50–90% 
substantial and 75–100% considerable heterogeneity [16]. 
Significance level of heterogeneity was set at p < 0.1. Pub-
lication bias was assessed by visual inspection of funnel plot 
and Egger’s linear regression test. Statistical significance 
was set at p < 0.05. All statistical analyses were conducted 




During the observational period from March 1 to April 15, 
2020, 101 patients (48.5% females, median age 66 [55–78]) 
with laboratory-confirmed COVID-19 have been admitted 
to participating hospitals. Two patients were still hospital-
ized at the time of data analysis. Overall, 74 of 101 (73.3%) 
patients showed severe or critical clinical course with neces-
sity of ICU treatment in 23 of 101 (22.8%) patients and in-
hospital death in 20 of 99 (20.2%) patients. In the entire mul-
ticenter cohort, a history of CVD was evident in 16 (15.8%) 
patients with higher frequencies in patients with severe 
course of COVID-19 when applying the National Health 
Commission guidelines on the Diagnosis and Treatment of 
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COVID-19 with dichotomized severity categories subsum-
ing categories mild, moderate in “non-severe” and catego-
ries severe and critical into “severe”. (20.3% vs. 3.7%, p = 
0.06) [10]. A history of CVD was also found to be more fre-
quent in patients with severe COVID-19 when severity was 
defined by necessity of intensive care vs. regular in-patient 
care (30.4% vs. 11.5%, p = 0.047) and in-hospital death vs. 
survival (35% vs. 11.4%, p = 0.02). A detailed description of 
demographic values, comorbidities and outcomes is shown 
in Table 1.
In multivariable analysis adjusting for selected covari-
ates (i.e., age, sex, arterial hypertension and diabetes mel-
litus), past history of CVD emerged as an independent pre-
dictor of severity of COVID-19 when severity was defined 
by necessity of ICU treatment (adjusted RR 4.81; 95% CI 
1.34-17.3; p = 0.02), but not by clinical severity (p = 0.55) 
or in-hospital death (p = 0.16).
Systematic review
A total of 3743 abstracts were retrieved from electronic data-
bases and 19 from bibliographies of published literature. 
After exclusion of duplicates and articles that did not fulfill 
eligibility criteria, 11 studies comprising 1805 laboratory-
confirmed COVID-19 patients (43.7% females, median ages 
ranging from 39 to 76 years) were included in quantitative 
data synthesis as described in detail in Table 2 [17–27]. 
The flowchart showing systematic screening and selection 
Table 1  Baseline demographic values, comorbidities and outcomes of multicenter cohort with COVID-19
(A) The upper part of the table shows the distribution of demographic and vascular risk profiles among patients with severe versus non-severe 
COVID-19 as defined by the National Health Commission guideline with subsuming categories mild and moderate in a “non-severe” category 
and moderate and critical in a “severe “ category [10]
(B) The lower part of the table shows the distribution of severity outcomes within our cohort of COVID-19 patients
IQR interquartile range, NHC National Health Commission, LEOSS Lean European Open Survey on SARS CoV II Infected Patients
a p values refer to between-group comparisons
b According to patients discharged at the time of analysis
(A) Baseline characteristics COVID-19 (n = 101) Severe (n = 74) Non-severe (n = 27) p  valuea
Demographic values
 Age, median (IQR) 66 (55–78) 72 (58–80) 53 (43–63)  < 0.001
 Women, n (%) 49 (48.5) 31 (41.9) 18 (66.7) 0.04
Past vascular risk factors, n (%)
 Arterial hypertension 61 (60.4) 53 (71.6) 8 (29.6)  < 0.001
 Hyperlipidemia 27 (26.7) 21 (28.4) 6 (22.2) 0.38
 Diabetes mellitus 27 (26.7) 24 (32.4) 3 (11.1) 0.04
 Atrial fibrillation 18 (17.8) 15 (20.3) 3 (11.1) 0.39
 Tobacco use 13 (12.9) 7 (9.5) 6 (22.2) 0.1
 Coronary heart disease 14 (13.9) 11 (14.9) 3 (11.1) 0.75
 Cerebrovascular disease 16 (15.8) 15 (20.3) 1 (3.7) 0.06
 Ischemic stroke 13 (12.9) 12 (16.2) 1 (3.7)
 Transient ischemic attack 2 (2) 2 (2.7) 0
 Intracerebral hemorrhage 1 (1) 1 (1.4) 0
(B) Severity outcomes COVID-19 (n = 101)









Intensive care treatment 23 (22.8)
 In-hospital death 20/99 (20.2)b
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process is depicted in Figure 2. All studies included patients 
from China and were of descriptive observational design. In 
order to avoid overlapping patient populations, we excluded 
two multicentric reports on Chinese cohorts from our quan-
titative synthesis because they partially comprised data 
from the same hospitals that were reported by other studies 
included in our analyses [1, 28]. None of the included stud-
ies reported by what criteria history of CVD was defined. 
Seven studies reported severity outcomes based on in-hos-
pital death (n = 5) [17, 18, 22–25] or necessity of intensive 
care (n = 2) [20, 21], whereas three studies [19, 26, 27] 
categorized clinical course of COVID-19 into “severe” and 
“non-severe” based on the National Health Commission 
guidelines on the Diagnosis and Treatment of COVID-19 
[10]. One study defined severity by length of hospitalization 
with a cut-off of 10 days [22]. Overall distribution of demo-
graphic data and vascular risk profiles among these stud-
ies was highly congruent with data from our local German 
multicenter cohort with relatively high frequencies of pre-
existing vascular risk factors, high ranges of median ages 
and a rather balanced male-to-female ratio.
Characteristics of included studies are detailed in Table 2.
Quantitative data synthesis
Pooled analysis including individual patient data from 
our multicenter cohort consisted of 1906 laboratory-
confirmed COVID-19 patients (43.9% females, median 
age ranging from 39 to 76 years). Patients with a his-
tory of CVD had higher risk of severe COVID-19 than 
those without (RR 2.07, 95% CI 1.52–2.81; p < 0.0001) 
when using a composite dichotomized outcome of sever-
ity subsuming all severity outcomes that were reported by 
each of the included studies. We noted substantial hetero-
geneity between studies (I2=69%, p = 0.001, Figure 3). 
Consistently, an increased risk of severe COVID-19 in 
Table 2  Study characteristics of included published studies
TIA transient ischemic attack, ICU intensive care unit, IQR interquartile range
a According to the quality rating scheme by the Oxford Centre for Evidence-based Medicine
b Overlapping cohort (publications on studies conducted at the same site introducing risk of overlap between study populations)
c,d Overlapping cohorts
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patients with a past medical history of CVD was also 
observed in sensitivity analyses separately consider-
ing clusters of studies that defined severity by clinical 
parameters (RR 1.44, 95% CI 1.22–1.71; p < 0.0001), 
necessity of intensive care (RR 2.79, 95% CI 1.83-4.24; 
p < 0.0001) and in-hospital death (RR 2.18, 95% CI 1.75-
2.7; p < 0.0001). Of these, evidence of low heterogeneity 
was observed for the ICU/non-ICU cluster (I2=35.3%, p = 
0.21), whereas no heterogeneity was noted for the clinical 
parameters cluster (I2=0%, p = 0.41) nor the in-hospital 
death cluster (I2=13.2%, p = 0.33).
When considering only published data from Chinese 
cohorts in pooled analysis (n = 1805), history of CVD 
was also associated with increased risk of severity of 
COVID-19 (RR 2.39, 95% CI 1.94–2.94; p < 0.0001) with 
similar results on sensitivity analyses for study-specific 
severity outcomes (clinical parameters: RR 1.83, 95% CI 
1.28–2.63; p = 0.001; necessity of intensive care: RR 2.9, 
95% CI 1.61-5.24; p < 0.0001 and in-hospital death: RR 
2.14, 95% CI 1.7–2.7; p < 0.0001). While there was evi-
dence of moderate between-study heterogeneity for addi-
tional analyses of the ICU/non-ICU cluster (I2=57.2%, p 
= 0.13), only low or absent heterogeneity was observed 
for the composite (I2=8.4%; p = 0.37), clinical severity 
(I2=0%; p = 0.83) and in-hospital death (I2=17.5%; p = 
0.3) outcome clusters.
Study quality
According to Oxford Centre for Evidence-based Medicine 
Rating Scale Quality, all included studies from published 
literature were consistently graded as level of evidence 4. 
Visual inspection of funnel plot showed symmetry in both 
studies plotted near the average, and those more distant 
from the average depending on their precision, thus shaping 
a distribution which is not suggestive of publication bias 
(Figure 4). No small study effect was seen on Egger’s linear 
regression test (p = 0.26).
Discussion
The major finding of our multicenter study is that a history 
of CVD is associated with an increased risk of developing 
severe course of COVID-19. This observation was consistent 
among pooled data which included descriptive observational 
studies from China during the rise of the pandemic and indi-
vidual multicenter patient data from the first few months 
after the local outbreak in Germany.
A strength of our analysis is that we synthesized data 
from two countries both hit heavily by the pandemic and 
both showing consistent findings in our analyses with 
respect to association of history of CVD and measures 
Fig. 2  Flowchart on identifica-
tion of studies on COVID-19 
eligible for quantitative data 
synthesis. PRISMA flowchart 
illustrating systematic screen-
ing and selection process of 
published observational studies 
reporting on laboratory-con-
firmed COVID-19 patients with 
data available on disease sever-
ity and past history of CVD
 Journal of Neurology
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of severity of COVID-19. Furthermore, data on distribu-
tion of demographic values as well as additional vascu-
lar comorbidities and their association with severity of 
COVID-19 was highly congruent between the German 
multicenter cohort and Chinese cohorts [17–27]. In par-
ticular, patients with severe COVID-19 were older, more 
frequently male and more often have had a history of arte-
rial hypertension or diabetes. Consistency of our observa-
tions is also reflected by low evidence of heterogeneity 
among studies with equal severity outcomes indicating 
probable generalizability to other populations. Another 
strength of our synthesized analysis is the strict exclu-
sion of overlapping study populations, which is especially 
important during the early phase of the pandemic where 
multiple descriptive studies were simultaneously derived 
from the ground zero region of Hubei, China. While an 
urgent need for data on the COVID-19 pandemic is appar-
ent, it is important to reduce potential sources of bias that 
might skew pooled effect estimates [29].
Our study is limited by variance in definitions used for 
severity of COVID-19 among studies extracted from the lit-
erature. However, risk factor association for history of CVD 
found in pooled analysis using a composite severity outcome 
subsuming all study-specific outcomes was consistent with 
those deriving from individual sensitivity analysis of clus-
ters of studies that applied the same definition of severity. 
Furthermore, data synthesized from the literature was lim-
ited by lack of explanation of how CVD was defined and 
therefore could not be analyzed regarding different types 
of cerebrovascular pathology in the context of COVID-19 
prognosis. In our multicenter cohort, the majority of previ-
ous cerebrovascular accidents that led to being classified as 
history of CVD were ischemic and only one of 101 patients 
had previous intracerebral hemorrhage. Whether etiology of 
previous CVD relates to risk of COVID-19 severity requires 
further investigation. Data on pre-existing pulmonary dis-
ease were not available to an extent that would have allowed 
a separate analysis on how this might have influenced the 
observed association between a history of CVD and severity 
of COVID-19.
Lastly, the association of past history of stroke and 
COVID-19 severity was dependent on cardiovascular risk 
profile on multivariable analysis in our multicenter cohort 
when severity was classified using clinical parameters or in-
hospital death versus survival. However, severity defined as 
necessity of intensive care showed an independent associa-
tion with history of stroke.
This might be explained by differences in disease progres-
sion at the time of admission due to pulmonary vulnerability 
of stroke survivors [8, 9]. However, it needs to be acknowl-
edged that we were not able to perform a multivariate analy-
sis in the cohorts identified through literature research as 
individual patient data were not available. Therefore, the 
actual number of patients who have had an actual history 
of CVD included in our multicenter cohort was relatively 
small (n = 16). Moreover, individual descriptions of stand-
ardized critical care admission approaches among hospi-
tals providing data to our multicenter analyses and those 
included in studies extracted from the literature were not 
consistently available. Therefore, a possible independency of 
the link between past history of CVD and COVID-19 sever-
ity requires further investigation. This analysis should be 
undertaken in cohorts with individual patient data available, 
preferably in the setting of a prospective observational study.
Since the outbreak of the pandemic, the impact of comor-
bidities on prognosis of COVID-19 has been extensively 
discussed with cardiovascular pathologies in the spotlight 
[5]. In particular, recent research has focused on traditional 
cardiovascular risk factors such as arterial hypertension and 
diabetes mellitus as predictors of disease severity [6, 7, 30]. 
However, it might be important to take a closer look into 
pre-existing brain vascular pathology of COVID-19 patients 
for several reasons. First, CVD is the leading cause of long-
term acquired disability which increases the risk of pulmo-
nary complications such as pneumonia [8, 9, 31]. While this 
association is not specific for infection caused by SARS-
CoV-2, it might partly explain why in our analysis patients 
with a history of CVD displayed a higher risk of severe 
course of COVID-19, which is considered a primarily res-
piratory disease [32]. Second, accumulative evidence sug-
gests that SARS-CoV-2 targets the central nervous system 
and may manifest with various neurological symptoms that 
might either be caused by direct neural damage or by neuro-
vascular accident such as acute ischemic stroke [33]. From 
a pathophysiological perspective, SARS-CoV-2 appears to 
increase risk of cardiovascular events, possibly mediated by 
systemic inflammation compromising functional and struc-
tural integrity of the vasculature by inflammatory injury of 
the endothelium and increasing blood coagulability [34]. 
In patients, who already had experienced a cerebrovascular 
accident, brain vasculature might be at increased vulnerabil-
ity toward these mechanisms. Lastly, patients with a history 
of CVD frequently have cardiovascular comorbidities that 
Fig. 3  Association of history of cerebrovascular disease and severe 
clinical manifestation of COVID-19 among included studies. Forest 
plots illustrating associations of history of CVD and severe clinical 
manifestation of COVID-19 for composite severity outcome subsum-
ing all definitions of severity as reported by included studies (a) as 
well as for clusters of studies defining severity by grading of clinical 
parameters (b), whether patients required intensive care (c), and in-
hospital death (d). Composite outcome analysis as well as assessment 
of each cluster included only studies that have not shown any over-
lap in study populations during full text evaluation. Individual patient 
data from German multicenter cohort were evaluated for severity 
based on the Chinese Clinical Guidance for COVID-19 Pneumonia 
Diagnosis and Treatment
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in turn might worsen prognosis of patients suffering from 
COVID-19 [28, 35].
Identification of populations at risk is one of the key fac-
tors in containing spread and reducing health care burden in 
epidemics [36]. This is even more important in a pandemic 
like COVID-19 where neither effective antiviral treatment 
nor vaccine is yet available to allow broad or targeted immu-
nization of individuals at risk. In this context, knowing that 
a history of CVD increases risk of developing more severe 
disease manifestation upon infection with SARS-CoV-2, 
viewed in conjunction with previous data on comorbidity-
related risk factor associations might be useful in designing 
risk-adapted prevention strategies.
Individuals who have a history of CVD are more likely 
to develop severe manifestation of COVID-19. Consistency 
among results in our pooled analyses indicates that this 
observation is generalizable beyond the studied regions in 
China and Germany. However, it remains to be answered 
whether the increased risk of severity observed in COVID-
19 patients included in our analyses can be explained by a 
past history of CVD per se or simply reflects the additive 
effects of concomitant cardiovascular risk factors.
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